NASDAQ:INSMInsmed Stock Price, Forecast & News

Insmed's stock was trading at $21.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INSM stock has increased by 44.4% and is now trading at $30.68.
View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Insmed.

Insmed is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Insmed.

Insmed Incorporated (NASDAQ:INSM) announced its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($0.64) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.58) by $0.06. The biopharmaceutical company earned $42.50 million during the quarter, compared to analysts' expectations of $34.51 million. Insmed had a negative return on equity of 87.35% and a negative net margin of 162.82%. The business's revenue for the quarter was up 41.7% on a year-over-year basis. During the same period in the prior year, the company earned ($0.81) EPS.
View Insmed's earnings history.

8 Wall Street analysts have issued twelve-month price targets for Insmed's shares. Their forecasts range from $20.00 to $56.00. On average, they expect Insmed's stock price to reach $42.00 in the next twelve months. This suggests a possible upside of 36.9% from the stock's current price.
View analysts' price targets for Insmed.

News articles about INSM stock have trended positive recently, according to InfoTrie. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Insmed earned a coverage optimism score of 2.1 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.
View the latest news about Insmed.

Some companies that are related to Insmed include GALAPAGOS NV/S (GLPG), Sarepta Therapeutics (SRPT), Dr.Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Mylan (MYL), Ascendis Pharma A/S (ASND), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Emergent Biosolutions (EBS), ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), Mirati Therapeutics (MRTX) and Myokardia (MYOK).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include AbbVie (ABBV), Geron (GERN), Johnson & Johnson (JNJ), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Intercept Pharmaceuticals (ICPT), Micron Technology (MU), Opko Health (OPK) and Amarin (AMRN).

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Insmed's stock is owned by a number of retail and institutional investors. Top institutional investors include Fairmount Funds Management LLC (1.00%), Principal Financial Group Inc. (0.52%), Candriam Luxembourg S.C.A. (0.29%), Frontier Capital Management Co. LLC (0.27%), Scout Investments Inc. (0.23%) and Swiss National Bank (0.22%). Company insiders that own Insmed stock include Alfred Altomari, Donald J Hayden Jr, John Goll, Melvin Md Sharoky, Orlov S Nicole Schaeffer, Roger Adsett, Steinar J Engelsen and William Lewis.
View institutional ownership trends for Insmed.

INSM stock was sold by a variety of institutional investors in the last quarter, including Fairmount Funds Management LLC, Mutual of America Capital Management LLC, Virtus ETF Advisers LLC, and SG Americas Securities LLC.
View insider buying and selling activity for Insmed.

INSM stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Frontier Capital Management Co. LLC, Principal Financial Group Inc., Oak Ridge Investments LLC, Scout Investments Inc., Swiss National Bank, First Trust Advisors LP, and WINTON GROUP Ltd. Company insiders that have bought Insmed stock in the last two years include Melvin Md Sharoky, Roger Adsett, Steinar J Engelsen, and William Lewis.
View insider buying and selling activity for Insmed.

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INSM stock can currently be purchased for approximately $30.68.

Insmed has a market capitalization of $3.10 billion and generates $136.47 million in revenue each year. The biopharmaceutical company earns $-254,340,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. Insmed employs 373 workers across the globe.

The official website for Insmed is www.insmed.com.

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]